IL33 and neoplasm: Twelve days after ACT (upon tumor response), we observed significantly more total CD8+ TILs and marked intratumoral expansion of transferred OT1 cells following PD1d/IL-2v/IL-33 OT1 ACT (Fig. 1c,d and Extended Data Fig. 3c), while PD1d/IL-2v OT1 or PD1d/IL-33 OT1 cells showed modest or minimal levels of tumor expansion, respectively.